-Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atri...
23andMe, a leading consumer genetics and research organization and nonprofit affiliate of the 23andMe Research Institute, today announced the launch of a...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often e...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, announced the d...
Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and developm...
dsm-firmenich, innovators in nutrition, health, and beauty, has announced the completion of a planned $10 million modernization program on its Schenectad...
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform ...
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxif...
CMIC Co., Ltd., a contract research organization (CRO) jointly owned by Blackstone and CMIC HOLDINGS Co. Ltd., announced a strategic partnership with...
Collaboration brings together clinical and claims-based quality intelligence with agentic AI to help healthcare organizations close care gaps and succeed...
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult pati...
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzuma...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene...
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit...
© 2026 Biopharma Boardroom. All Rights Reserved.
